CD36 and type 2 diabetes mellitus: Because previous studies have shown that CD36 and ACAT-1 levels are mainly associated with PI3K and PKC [17–19], a DPP-4 inhibitor can possibly regulate CD36 and ACAT-1 expressions via the PI3K/PKC signaling pathway in macrophages of diabetic mice and T2D patients.